Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 6000 participants.

Also called NCT06909565

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 6,000 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06909565
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06909565. Randomized; quadruple masking; primary purpose prevention. Start 2025-07-23 (actual); primary completion 2029-10 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention
Acronym
V-INTERVENTION
Condition
Peripheral Endovascular Intervention
Intervention (Drug)
Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
Intervention (Drug)
Normal Saline (Placebo)
Lead sponsor
Duke University (class: other)
Collaborator
Novartis Pharmaceuticals (class: industry)
Collaborator
Colorado Prevention Center (class: other)
Collaborator
Mount Sinai Hospital, New York (class: other)

Record details

Record id
cardio:ct-nct06909565
Content hash
ddfcb49ff8dc8d2c8cf0035d7e157ba93917a91078e76e1b15811bafffa4da60